| Dr William J Bernhardt-purdy, LMSW, LPC, LMAC, DSW | |
|
220 Cornell Ave, Liberal, KS 67901-3006 | |
| (620) 366-9782 | |
| Not Available |
| Full Name | Dr William J Bernhardt-purdy |
|---|---|
| Gender | Male |
| Speciality | Social Worker |
| Location | 220 Cornell Ave, Liberal, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639328644 | NPI | - | NPPES |
| K02795165 | Other | KS | DL |
| Mailing Address | Practice Location Address |
|---|---|
| Dr William J Bernhardt-purdy, LMSW, LPC, LMAC, DSW 220 Cornell Ave, Liberal, KS 67901-3006 Ph: (620) 366-9782 | Dr William J Bernhardt-purdy, LMSW, LPC, LMAC, DSW 220 Cornell Ave, Liberal, KS 67901-3006 Ph: (620) 366-9782 |
News Archive
Published in a recent medRxiv* paper, researchers from South Africa, the United Kingdom, and Brazil found that these mutations in SARS-CoV-2 lineages are localized to South Africa. These unique strains, not found elsewhere in the world, are thought to have contributed around 42% to the country's total infection rate.
Antares Pharma, Inc. announced that it has received a Notice of Allowance from the U.S. Patent Trade Office on a patent application for the VIBEX QuickShot device, the latest advancement in its proprietary line of VIBEX auto-injector systems.
Penn State Health and Catholic Health Initiatives have completed the transfer of ownership of CHI's affiliate, St. Joseph Regional Health Network (St. Joseph) in Reading, Pa., to Penn State Health.
A consortium of Louisiana's leading biomedical research institutions, headed by the Pennington Biomedical Research Center, partnered with LSU and Tulane Health Science Centers in New Orleans, will investigate the mysteries of "long COVID" under a National Institutes of Health award.
EpiCept Corporation today announced that the Israeli Ministry of Health has approved the marketing application for Ceplene®, indicated for remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. Megapharm Ltd. is EpiCept's partner in Israel and upon Ministry of Health approval of labeling and other technical matters the company is expected to launch Ceplene® in the first quarter of 2011.
› Verified 8 days ago